Table 4.
eGFRcystatin C/eGFRcreatinine ratio | HR (95% CI) | ||
---|---|---|---|
| |||
<0.9 | 0.9–1.1 (Reference) | >1.1 | |
baPWV ≥1,550 cm/sec | |||
Total subjects | |||
Eventsa | 51 (63.0) | 74 (42.0) | 206 (34.2) |
Model 1 | 1.55 (1.08–2.23) | 1 | 1.03 (0.78–1.35) |
Model 2 | 1.60 (1.11–2.30) | 1 | 0.99 (0.74–1.32) |
Subjects without CKD | |||
Eventsa | 14 (45.2) | 34 (32.4) | 106 (29.9) |
Model 1 | 2.38 (1.26–4.50) | 1 | 0.97 (0.65–1.45) |
Model 2 | 2.97 (1.53–5.74) | 1 | 1.00 (0.65–1.54) |
Subjects with CKD | |||
Eventsa | 37 (74.0) | 40 (56.3) | 100 (40.3) |
Model 1 | 1.60 (1.01–2.54) | 1 | 1.05 (0.71–1.55) |
Model 2 | 1.44 (0.90–2.30) | 1 | 0.96 (0.64–1.44) |
| |||
Carotid plaque | |||
Total subjects | |||
Eventsb | 31 (38.3) | 38 (21.6) | 104 (17.2) |
Model 1 | 1.78 (1.09–2.88) | 1 | 0.90 (0.61–1.32) |
Model 2 | 1.77 (1.07–2.91) | 1 | 0.88 (0.59–1.32) |
Subjects without CKD | |||
Eventsb | 8 (25.8) | 16 (15.2) | 3 (14.9) |
Model 1 | 3.50 (1.47–8.36) | 1 | 0.78 (0.44–1.38) |
Model 2 | 4.58 (1.81–11.60) | 1 | 0.75 (0.40–1.39) |
Subjects with CKD | |||
Eventsb | 23 (46.0) | 22 (31.0) | 51 (20.6) |
Model 1 | 1.71 (0.94–3.13) | 1 | 0.90 (0.53–1.53) |
Model 2 | 1.65 (0.89–3.07) | 1 | 0.92 (0.53–1.61) |
Values are presented as number (%). Model 1: adjusted for age, sex, body mass index, hypertension, duration of diabetes, and glycosylated hemoglobin; Model 2: adjusted for Model 1+pulse pressure, antiplatelet therapy, intima-media thickness, ankle-brachial index, total cholesterol, high-density lipoprotein cholesterol, and uric acid.
eGFR, estimated glomerular filtration rate; baPWV, brachial-ankle pulse wave velocity; HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease.
“Events” is the number of individuals who have baPWV ≥1,550 cm/sec,
“Events” is the number of individuals who have carotid plaque.